News

BioPharma Dive4d
FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche
The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...
pharmaphorum4d
FDA clears Nuvation's first product Ibtrozi, for lung cancer
Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...
TMCnet5h
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.
“Onco360 is grateful for the opportunity to partner with the team at Nuvation Bio and become a specialty pharmacy provider for IBTROZI,” said Benito Fernandez, Chief Commercial Officer at Onco360. “We ...
US FDA approves Nuvation Bio's rare lung cancer drug
The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and ...
Nuvation Bio: Judgement Day Grows Closer
Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support ...
PharmExec4d
FDA Approves Nuvation Bio’s Ibtrozi for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Approval was based on results from the Phase II TRUST-I and TRUST-II trials, which demonstrated confirmed overall response ...
PMLive4d
FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer
The US Food and Drug Administration (FDA) has approved Nuvation Bio’s Ibtrozi (taletrectinib) to treat adults with a rare and ...
Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval
FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing ...
US FDA approves Nuvation Bio's lung cancer therapy
The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of ...